Company news

Heidelberg Pharma AG news in 2026

Heidelberg Pharma AG's news releases, calls and decks from 2026, newest first.

View company

Heidelberg Pharma to Present New Clinical Data on its ATAC Candidates at the ASH Annual Meeting 2026

November 4, 2026

Heidelberg Pharma Reports on the First Nine Months of Financial Year 2026

October 15, 2026

Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026

September 24, 2026

Heidelberg Pharma to Present New Clinical Data on Lead ATAC Candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026

September 7, 2026

Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

August 28, 2026

Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China

August 26, 2026

Heidelberg Pharma Reports on First Half-Year 2026 and the Positive Course of Business

July 15, 2026

Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026

June 23, 2026

Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2026

April 29, 2026

Heidelberg Pharma Announces Change in Executive Board

April 17, 2026

Heidelberg Pharma AG: Heidelberg Pharma Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101

April 9, 2026

Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026

April 4, 2026

Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026

March 26, 2026

Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China

March 18, 2026

Decks in 2026